The Cancer SENESCopedia: A delineation of cancer cell senescence.


Journal

Cell reports
ISSN: 2211-1247
Titre abrégé: Cell Rep
Pays: United States
ID NLM: 101573691

Informations de publication

Date de publication:
27 07 2021
Historique:
received: 21 12 2020
revised: 29 05 2021
accepted: 02 07 2021
entrez: 28 7 2021
pubmed: 29 7 2021
medline: 10 2 2022
Statut: ppublish

Résumé

Cellular senescence is characterized as a stable proliferation arrest that can be triggered by multiple stresses. Most knowledge about senescent cells is obtained from studies in primary cells. However, senescence features may be different in cancer cells, since the pathways that are involved in senescence induction are often deregulated in cancer. We report here a comprehensive analysis of the transcriptome and senolytic responses in a panel of 13 cancer cell lines rendered senescent by two distinct compounds. We show that in cancer cells, the response to senolytic agents and the composition of the senescence-associated secretory phenotype are more influenced by the cell of origin than by the senescence trigger. Using machine learning, we establish the SENCAN gene expression classifier for the detection of senescence in cancer cell samples. The expression profiles and senescence classifier are available as an interactive online Cancer SENESCopedia.

Identifiants

pubmed: 34320349
pii: S2211-1247(21)00858-5
doi: 10.1016/j.celrep.2021.109441
pmc: PMC8333195
pii:
doi:

Substances chimiques

Aniline Compounds 0
Azepines 0
MLN 8237 0
Pyrimidines 0
Senotherapeutics 0
Sulfonamides 0
Etoposide 6PLQ3CP4P3
navitoclax XKJ5VVK2WD

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

109441

Informations de copyright

Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests R.B. is the founder of the company Oncosence (https://www.oncosence.com), which aims to develop senescence-inducing and senolytic compounds to treat cancer. L.F.A.W. received research funding from Genmab BV.

Références

BMB Rep. 2014 Feb;47(2):51-9
pubmed: 24411464
Nat Med. 2020 May;26(5):693-698
pubmed: 32405063
Cell Cycle. 2015;14(3):297-304
pubmed: 25564883
Nat Rev Cancer. 2014 Aug;14(8):547-58
pubmed: 25030953
Mol Cell. 2018 Dec 20;72(6):970-984.e7
pubmed: 30449723
Int J Cancer. 2020 Mar 1;146(5):1299-1306
pubmed: 31444973
Cancer Res. 2021 Mar 1;81(5):1347-1360
pubmed: 33323381
Science. 2016 Oct 28;354(6311):472-477
pubmed: 27789842
Curr Med Chem Anticancer Agents. 2005 Jul;5(4):363-72
pubmed: 16101488
Cancer Res. 2005 Apr 1;65(7):2795-803
pubmed: 15805280
Oncogene. 2008 Oct 9;27(46):5975-87
pubmed: 18711403
Annu Rev Pathol. 2010;5:99-118
pubmed: 20078217
Cell. 2019 Oct 31;179(4):813-827
pubmed: 31675495
J Stat Softw. 2010;33(1):1-22
pubmed: 20808728
Biochem Pharmacol. 1999 Apr 1;57(7):727-41
pubmed: 10075079
BMC Bioinformatics. 2018 Nov 6;19(1):404
pubmed: 30400809
Aging Cell. 2020 Apr;19(4):e13142
pubmed: 32233024
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
J Pharm Pharmacol. 2013 Feb;65(2):157-70
pubmed: 23278683
Nat Commun. 2020 Apr 24;11(1):1996
pubmed: 32332723
Nucleic Acids Res. 2012 May;40(10):4288-97
pubmed: 22287627
Cell Commun Signal. 2017 May 4;15(1):17
pubmed: 28472950
Curr Biol. 2017 Sep 11;27(17):2652-2660.e4
pubmed: 28844647
Front Oncol. 2015 Aug 24;5:189
pubmed: 26380220
EXCLI J. 2015 Jan 19;14:95-108
pubmed: 26600742
Biology (Basel). 2020 Dec 21;9(12):
pubmed: 33371508
Nature. 2018 Jan 4;553(7686):96-100
pubmed: 29258294
PLoS Biol. 2020 Jan 16;18(1):e3000599
pubmed: 31945054
Leukemia. 2016 Mar;30(3):761-4
pubmed: 26174630
PLoS Biol. 2008 Dec 2;6(12):2853-68
pubmed: 19053174
Oncogene. 2021 Mar;40(11):2065-2080
pubmed: 33627784
Exp Cell Res. 1965 Mar;37:614-36
pubmed: 14315085
Cell Death Differ. 2020 Nov;27(11):3097-3116
pubmed: 32457483
J Biol Chem. 2003 Apr 4;278(14):11731-4
pubmed: 12551891
Nucleic Acids Res. 2019 Aug 22;47(14):7294-7305
pubmed: 31251810
Cell. 2020 Apr 16;181(2):424-441.e21
pubmed: 32234521
Mol Cancer. 2014 Apr 30;13:98
pubmed: 24779770
Nat Cell Biol. 2020 Jul;22(7):842-855
pubmed: 32514071
PLoS One. 2011;6(7):e21800
pubmed: 21789182
Nat Med. 2016 Jan;22(1):78-83
pubmed: 26657143
Cancers (Basel). 2020 Nov 29;12(12):
pubmed: 33260316
Cell Syst. 2015 Dec 23;1(6):417-425
pubmed: 26771021
Aging Cell. 2016 Jun;15(3):428-35
pubmed: 26711051
Cell Rep. 2017 Nov 28;21(9):2433-2446
pubmed: 29186682
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Nature. 2009 Nov 5;462(7269):108-12
pubmed: 19847166
Oncogene. 2014 Jul 3;33(27):3550-60
pubmed: 23955083
J Natl Cancer Inst. 2010 Oct 20;102(20):1536-46
pubmed: 20858887
Nature. 2018 Oct;562(7728):578-582
pubmed: 30232451
Cell Rep. 2017 Oct 17;21(3):773-783
pubmed: 29045843
Cancer Res. 1999 Aug 1;59(15):3761-7
pubmed: 10446993
BMC Bioinformatics. 2013 Jan 16;14:7
pubmed: 23323831
Aging Cell. 2017 Oct;16(5):1043-1050
pubmed: 28699239
Cytokine. 2019 May;117:15-22
pubmed: 30776684
Cancer Discov. 2017 Feb;7(2):165-176
pubmed: 27979832
Cancer Metastasis Rev. 2010 Jun;29(2):273-83
pubmed: 20390322
Front Oncol. 2017 Nov 23;7:278
pubmed: 29218300
J Formos Med Assoc. 2020 Dec 18;:
pubmed: 33342707
Cell Cycle. 2014;13(24):3927-37
pubmed: 25483067
EMBO J. 2021 Mar 15;40(6):e104296
pubmed: 33459422
Nucleic Acids Res. 2005 Jan 1;33(Database issue):D537-43
pubmed: 15608256
Int J Radiat Oncol Biol Phys. 2017 Oct 1;99(2):353-361
pubmed: 28479002
Hepat Oncol. 2017 Oct;4(4):123-127
pubmed: 29230285
Nat Med. 2018 Jul;24(7):961-967
pubmed: 29808006
BMC Genomics. 2009 Mar 30;10:137
pubmed: 19331659
Nature. 2019 Oct;574(7777):268-272
pubmed: 31578521
Nat Med. 2020 May;26(5):688-692
pubmed: 32405062
Trends Mol Med. 2010 May;16(5):238-46
pubmed: 20444648
Nat Med. 2019 Dec;25(12):1938-1947
pubmed: 31792461
Cell. 2002 May 3;109(3):335-46
pubmed: 12015983
Cancer Chemother Pharmacol. 2014 Sep;74(3):593-602
pubmed: 25053389
Cell. 2003 Jun 13;113(6):703-16
pubmed: 12809602
Aging Cell. 2017 Aug;16(4):693-703
pubmed: 28401730
Mol Ther. 2013 Apr;21(4):825-33
pubmed: 23403494
Br J Cancer. 2010 Aug 10;103(4):505-9
pubmed: 20628375

Auteurs

Fleur Jochems (F)

Division of Molecular Carcinogenesis, Oncode Institute, Netherlands Cancer Institute, Plesmanlaan 121, 1066 Amsterdam, the Netherlands.

Bram Thijssen (B)

Division of Molecular Carcinogenesis, Oncode Institute, Netherlands Cancer Institute, Plesmanlaan 121, 1066 Amsterdam, the Netherlands.

Giulia De Conti (G)

Division of Molecular Carcinogenesis, Oncode Institute, Netherlands Cancer Institute, Plesmanlaan 121, 1066 Amsterdam, the Netherlands.

Robin Jansen (R)

Division of Molecular Carcinogenesis, Oncode Institute, Netherlands Cancer Institute, Plesmanlaan 121, 1066 Amsterdam, the Netherlands.

Ziva Pogacar (Z)

Division of Molecular Carcinogenesis, Oncode Institute, Netherlands Cancer Institute, Plesmanlaan 121, 1066 Amsterdam, the Netherlands.

Kelvin Groot (K)

Division of Molecular Carcinogenesis, Oncode Institute, Netherlands Cancer Institute, Plesmanlaan 121, 1066 Amsterdam, the Netherlands.

Liqin Wang (L)

Division of Molecular Carcinogenesis, Oncode Institute, Netherlands Cancer Institute, Plesmanlaan 121, 1066 Amsterdam, the Netherlands.

Arnout Schepers (A)

Division of Molecular Carcinogenesis, Oncode Institute, Netherlands Cancer Institute, Plesmanlaan 121, 1066 Amsterdam, the Netherlands.

Cun Wang (C)

Division of Molecular Carcinogenesis, Oncode Institute, Netherlands Cancer Institute, Plesmanlaan 121, 1066 Amsterdam, the Netherlands.

Haojie Jin (H)

Division of Molecular Carcinogenesis, Oncode Institute, Netherlands Cancer Institute, Plesmanlaan 121, 1066 Amsterdam, the Netherlands.

Roderick L Beijersbergen (RL)

Division of Molecular Carcinogenesis, The NKI Robotics and Screening Center, Netherlands Cancer Institute, Plesmanlaan 121, 1066 Amsterdam, the Netherlands.

Rodrigo Leite de Oliveira (R)

Division of Molecular Carcinogenesis, Oncode Institute, Netherlands Cancer Institute, Plesmanlaan 121, 1066 Amsterdam, the Netherlands.

Lodewyk F A Wessels (LFA)

Division of Molecular Carcinogenesis, Oncode Institute, Netherlands Cancer Institute, Plesmanlaan 121, 1066 Amsterdam, the Netherlands; Faculty of EEMCS, Delft University of Technology, Delft, the Netherlands. Electronic address: l.wessels@nki.nl.

René Bernards (R)

Division of Molecular Carcinogenesis, Oncode Institute, Netherlands Cancer Institute, Plesmanlaan 121, 1066 Amsterdam, the Netherlands. Electronic address: r.bernards@nki.nl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH